Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus

Lupus Science and Medicine

Volumn 3, Issue 1, 2016, Pages

  Carli, L ^a,b   Tani, C ^b   Spera, V ^b   Vagelli, R ^b   Vagnani, S ^b   Mazzantini, M ^b   Di Munno, O ^b   Mosca, M ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Fragility fractures; Osteoporosis; Premenopausal women; Risk factors; Systemic Lupus Erythematosus

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; CALCIUM; COLECALCIFEROL; GLUCOCORTICOID;

ADULT; AGE; ARTICLE; BODY MASS; BONE DENSITY; BONE METABOLISM; CHRONIC KIDNEY FAILURE; COMORBIDITY; DISEASE DURATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRAGILITY FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; MIDDLE AGED; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OSTEOPOROSIS; PREMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; SEX; SMOKING HABIT; SYSTEMIC LUPUS ERYTHEMATOSUS; UNIVARIATE ANALYSIS;

EID: 84971547743     PISSN: None     EISSN: 20538790     Source Type: Journal    
DOI: 10.1136/lupus-2015-000098     Document Type: Article

References (33)

1. Di Munno O, Mazzantini M, Delle Sedie A, et al. Risk factors for osteoporosis in female patients with systemic lupus erythematosus. Lupus 2004;13:724-30.
2. Ramsey-Goldman R, Dunn JE, Huang CF, et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum 1999;42:882-90.
3. Grossman JM, Gordon R, Ranganath VK, et al. American college of rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 2010;62:1515-26.
4. Di Munno O, Delle Sedie A. Prevention and treatment of glucocorticoid-induced osteoporosis in International and italian scenarios. Reumatismo 2011;63:67-79.
5. Rodrigues Pereira RM, Freire de Carvalho J, Paula AP, et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev Bras Rheumatol 2012;52:569-93.
6. Kaji H, Yamauchi M, Chihara K, et al. The threshold of bone mineral density for vertebral fractures in female patients with glucocorticoid-induced osteoporosis. Endocr J 2006;53:27-34.
7. Maricic M, Gluck O. Densitometry in glucocorticoid-induced osteoporosis. J Clin Densitometry 2004;7:359-63.
8. Yee C-S, Crabtree N, Skan J, et al. Prevalence and predictors of fragility fracture in systemic lupus erythematosus. Ann Rheum Dis 2005;64:111-13.
9. Petri M. Muscoloskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. Arthritis Care Res 1995;8:137-45.
10. Formiga F, Moga I, Nolla JM, et al. Loss of bone mineral density in premenopausal women with systemic lupus erythematosus. Ann Rheum Dis 1995;54:274-6.
11. Mosca M, van Vollenhoven R. New drugs in systemic lupus erythematosus: when to start and when to stop. Clin Exp Rheumatol 2013;31(4 Suppl 78):S82-5.
12. Yee CS, Crabtree N, Skan J, et al. Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann Rheum Dis 2005;64:111-13.
13. Briot K, Cortet B, Roux C, et al. 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. Joint Bone Spine 2014;81:493-501.
14. Natsui K, Tanaka K, Suda M, et al. High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int 2006;17:105-8.
15. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725. doi:10.1002/ 1529-0131(199709)40:91725::AID-ART293.0.CO;2-Y
16. Soules MR, Sherman S, Parrott E, et al. Executive summary: stages of Reproductive Aging Workshop (STRAW). Fertil Steril 2001;76:874-88.
17. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney inter 2013; 3 (Suppl):1-150.
18. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994;4:368-81.
19. Adami S, Romagnoli E, Carnevale V, et al. Guidelines on prevention and treatment of Vitamin D deficiency. Reumatismo 2011;63:129-47.
20. Lee C, Almagor O, Dunlop DD, et al. Self-reported fractures and associated factors in women with systemic lupus erythematosus. J Rheumatol 2007;34:2018-23.
21. Bultink IE, Harvey NC, Lalmohamed A, et al. Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom. Osteoporos Int 2014;25:1275-83.
22. Mok CC. Vitamin D and systemic lupus erythematosus: an update. Expert Rev Clin Immunol 2013;9:453-63.
23. Ruiz-Irastorza G, Egurbide MV, Olivares N, et al. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology 2008;47:920-3.
24. Pakpoor J, Pakpoor J. Vitamin D deficiency and systemic lupus erythematosus: cause or consequence? Oman Med J 2013;28:295.
25. Attar SM, Siddiqui AM. Vitamin d deficiency in patients with systemic lupus erythematosus. Oman Med J 2013;28:42-7.
26. Gatenby P, Lucas R, Swaminathan A. Vitamin D deficiency and risk for rheumatic diseases: an update. Curr Opin Rheumatol 2013;25:184-91.
27. Davidson ZF, Walker KZ, Truby H. Do glucocorticosteroids alter Vitamin D status? A systematic review with meta-analyses of observational studies. J Clin Endocrinol Metab 2012;97:738-44.
28. Monticielo OA, Brenol JC, Chies JA, et al. The role of BsmI and FokI Vitamin D receptor gene polymorphisms and serum 25-hydroxyVitamin D in Brazilian patients with systemic lupus erythematosus. Lupus 2012;21:43-52.
29. Kramer H, Berns JS, Choi MJ, et al. 25-hydroxyVitamin D testing and supplementation in CKD: an NKF-KDOQI controversies report. Am J Kidney Dis 2014;64:499-509.
30. Rezaieyazdi Z, Falsoleiman H, Khajehdaluee M, et al. Reduced bone density in patients on long-term warfarin. Int J Rheum Dis 2009;12:130-5.
31. Riess H, Loew A, Himmelreich G. Secondary osteoporosis induced by anticoagulants? Orthopade 2001;30:451-5.
32. Panday K, Gona A, Humphrey MB. Medication-induced osteoporosis: screening and treatment strategies. Ther Adv Muscoloskel Dis 2014;6:185-202.
33. Fangtham N, Petri M. 2013 update: hopkins lupus cohort. Curr Rheumatol Rep 2013;15:360.